Pfanstiel Steven's most recent trade in Marinus Pharmaceuticals Inc was a trade of 4,657 Common Stock done at an average price of $1.1 . Disclosure was reported to the exchange on Aug. 5, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Sale of securities on an exchange or to another person at price $ 1.13 per share. | 05 Aug 2024 | 4,657 | 79,773 (0%) | 0% | 1.1 | 5,262 | Common Stock |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 57,300 | 57,300 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 12,733 | 84,430 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Sale of securities on an exchange or to another person at price $ 9.97 per share. | 16 Feb 2024 | 3,092 | 71,697 (0%) | 0% | 10.0 | 30,827 | Common Stock |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 114,600 | 114,600 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Pfanstiel Steven | CFO AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 25,465 | 74,789 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Sale of securities on an exchange or to another person at price $ 9.54 per share. | 07 Aug 2023 | 2,790 | 49,338 (0%) | 0% | 9.5 | 26,617 | Common Stock |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Sale of securities on an exchange or to another person at price $ 8.93 per share. | 07 Aug 2023 | 14 | 49,324 (0%) | 0% | 8.9 | 125 | Common Stock |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 126,585 | 126,585 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 28,130 | 52,128 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 7,448 | 23,998 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 74,475 | 74,475 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 16,550 | 16,550 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 220,000 | 220,000 | - | - | Stock option (right to buy) |